According to international treatment guidelines, as long as acute coronary heart disease, including unstable angina pectoris or acute myocardial infarction occurs, patients should take dual antiplatelet drugs for 12 months, using different antiplatelet mechanisms to prevent thrombosis . Dr. Song Sixian said that according to the research, the use of 12-month dual-antibody therapy in patients with acute coronary heart disease, compared with only 1-month dual-antibody therapy, the use of 12-month dual-antibody therapy can effectively reduce cardiovascular deaths, including stroke. , myocardial infarction, etc. When receiving antiplatelet drugs, Asians have a higher risk of cerebral hemorrhage and gastrointestinal hemorrhage than Europe and the United States [8, 9].
Dr. Song Sixian said that patients can discuss with their Photo Restoration Service physicians the appropriate antiplatelet drugs to obtain a better balance between efficacy and safety. Balanced, can prevent myocardial infarction without increasing the risk of bleeding. If you find that it is easy to bruise, urinate, or defecate, please report to your doctor immediately so that you can adjust the medicine in a timely manner. Intimate reminder: stay away from the three highs and reduce the recurrence crisis of ischemic events such as stroke and myocardial infarction Atherosclerosis is formed over time. Everyone should control the risk factors such as hypertension, hyperglycemia, and hyperlipidemia, and maintain a healthy lifestyle to reduce the risk of cardiovascular disease. If you have had a stroke or myocardial infarction, you should pay more attention to secondary prevention, and take dual antiplatelet drugs as instructed. Dr. Song Sixian reminded that if you observe side effects such as bleeding and gastrointestinal discomfort, please explain to the doctor in detail, and then adjust immediately.
References García Rodríguez LA et al. PLoS ONE. 2016;11(8):e0160046. Ministry of Health and Welfare National Health Service/Awareness of Coronary Heart Disease Conlon KC, Rajkovich NB, White-Newsome JL, Larsen L, O'Neill MS. Preventing cold-related morbidity and mortality in a changing climate. Maturitas. 2011 Jul;69(3):197-202. doi: 10.1016/j .maturitas.2011.04.004. Epub 2011 May17. PMID: 21592693; PMCID: PMC3119517. Smits PC, Frigoli E, Tijssen J, Jüni P, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stankovic G, Iñiguez A, Schultz C, Kornowski R, Ong PJL, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Heg D, Valgimigli M; MASTER DAPT Investigators. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. Circulation. 2021 Oct12;144(15):1196-1211. doi: 10.1161/CIRCULATIONAHA.121.056680. Epub 2021 Aug 29. PMID: 34455849; PMCID: PMC8500374. 2017 Taiwan lipid guidelines for high risk patient.